Poolbeg Pharma (LON:POLB) Stock Price Down 13.6% – Should You Sell?

Shares of Poolbeg Pharma PLC (LON:POLB) were down 13.6% during mid-day trading on Tuesday . The company traded as low as GBX 5.96 and last traded at GBX 6.05. Approximately 23,044,447 shares were traded during mid-day trading, an increase of 1,199% from the average daily volume of 1,774,020 shares. The stock had previously closed at GBX 7.

Analysts Set New Price Targets

Separately, Shore Capital Group reiterated a “house stock” rating on shares of Poolbeg Pharma in a report on Monday.

Poolbeg Pharma Stock Down 1.9%

The company has a 50 day moving average of GBX 6.47 and a 200 day moving average of GBX 5.12. The firm has a market cap of £43.57 million, a price-to-earnings ratio of -6.57 and a beta of 1.81.

Poolbeg Pharma (LON:POLB) last released its quarterly earnings results on Tuesday, April 28th. The company reported GBX (0.94) earnings per share for the quarter. As a group, equities research analysts expect that Poolbeg Pharma PLC will post -0.68 earnings per share for the current fiscal year.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.